On Friday, Novo Nordisk A/S NVO launched headline outcomes from the STEP UP Section 3b trial within the world STEP program.
Semaglutide 2.4 mg is marketed under the brand title Wegovy. STEP UP is a 72-week efficacy and security trial investigating subcutaneous semaglutide 7.2 mg in comparison with semaglutide 2.4 mg and placebo, all administered as soon as weekly.
Additionally Learn: Novo Nordisk’s Hybrid Weight Loss Drug Falls Brief On Expectations, Inventory Plunges
The trial included 1,407 randomized adults with weight problems. All therapy arms have been along side way of life intervention.
The trial achieved its major endpoint by demonstrating a statistically vital and superior weight reduction at week 72 with semaglutide 7.2 mg versus placebo.
When evaluating the consequences of therapy if all folks adhered to therapy from a imply baseline physique weight of 113 kg, folks handled with semaglutide 7.2 mg achieved a superior weight lack of 20.7% after 72 weeks in comparison with a discount of 17.5% with semaglutide 2.4 mg and a couple of.4% with placebo.
As well as, 33.2% of those that acquired semaglutide 7.2 mg achieved a weight lack of 25% or extra after 72 weeks, in comparison with 16.7% with semaglutide 2.4 mg and 0.0% with placebo.
When making use of the therapy coverage estimand, folks handled with semaglutide 7.2 mg achieved a superior weight lack of 18.7% in comparison with a discount of 15.6% with semaglutide 2.4 mg and three.9% with placebo.
Within the trial, semaglutide 7.2 mg appeared to have a protected and well-tolerated profile.
The outcomes from the second semaglutide 7.2 mg section 3 trial, STEP UP T2D, in adults with kind 2 diabetes and weight problems are anticipated throughout the subsequent few months.
Detailed outcomes from the STEP UP trial are anticipated to be offered at a scientific convention in 2025.
Value Motion: NVO inventory is down 4.37% at $79.44 through the premarket session on the final verify on Friday.
Learn Subsequent:
Picture by Tobias Arhelger by way of Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
